Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)

NCT04733118 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04733118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04733118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 5, 2021
Completion date
March 31, 2028
Enrollment
393 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer